VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
SUPN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
SUPNSupernus Pharmaceuticals, Inc.
$28.96$3.5B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksSUPNFinancials

Supernus Pharmaceuticals, Inc. (SUPN) Income Statement

18Y historyFree accessUpdated daily

Revenue reached $356.0M in 2026Q3 with an operating margin of 50.8%, but quarterly profitability has been volatile, with operating margin ranging from 23.2% to -31.4% over the past ten quarters.

Income StatementBalance SheetCash FlowRatios

SUPN Income Statement

Annual statement

SUPN Income Statement

Supernus Pharmaceuticals, Inc. (SUPN) annual income statement — 18-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08
Sales/Revenue1.37B1.24B1.19B1.09B901M791M647M785M959.92M1.15B968.89M144.43M122.05M12.02M1.48M803K106K37.92M8.89M
Revenue Growth %16.34%4.29%8.69%21.31%13.91%22.26%-17.58%-18.22%-16.39%18.5%570.85%18.34%915.43%712.09%84.31%657.55%-99.72%326.65%-
Cost of Goods Sold204M246M231M174M151M127M97M140M134.68M122.9M110.81M8.42M5.76M1.1M00-13.4M-8.59M336
COGS % of Revenue-19.85%19.44%15.92%16.76%16.06%14.99%17.83%14.03%10.7%11.44%5.83%4.72%9.19%---12645.28%-22.65%0%
Gross Profit1.17B993M957M919M750M664M550M645M825.25M1.03B858.08M136M116.29M10.91M1.48M803K13.51M46.51M8.89M
Gross Margin %85.15%80.15%80.56%84.08%83.24%83.94%85.01%82.17%85.97%89.3%88.56%94.17%95.28%90.81%100%100%12745.28%122.65%100%
Gross Profit Growth %-3.76%4.13%22.53%12.95%20.73%-14.73%-21.84%-19.5%19.48%530.92%16.96%965.39%637.5%84.31%-94.06%-70.95%423.29%-
Operating Expenses570M728M925M1.07B831M451M706M467M508.14M601.89M520.16M118.34M92.06M72.83M43.65M38.55M40.23M33.91M34.75M
OpEx % of Revenue-58.76%77.86%98.35%92.23%57.02%109.12%59.49%52.94%52.42%53.69%81.94%75.43%606%2949.26%4801.37%37951.89%89.41%390.93%
Selling, General & Admin520M634M618M569M469M431M649M395M444.14M508.4M411.18M89.2M72.47M55.59M20.13M7.93M5.08M4.65M4.29M
SG&A % of Revenue-51.17%52.02%52.06%52.05%54.49%100.31%50.32%46.27%44.28%42.44%61.76%59.38%462.52%1360.27%987.3%4792.45%12.26%48.23%
Research & Development50M97M107M116M74M52M40M53M63.99M93.49M108.98M29.14M19.59M17.25M23.52M30.63M35.15M29.26M30.46M
R&D % of Revenue-7.83%9.01%10.61%8.21%6.57%6.18%6.75%6.67%8.14%11.25%20.17%16.05%143.48%1588.99%3814.07%33159.43%77.15%342.7%
Other Operating Expenses0-3M200M390M288M-32M17M19M00038K39K101K0117K542K00
Operating Income600M265M32M-156M-81M213M-156M178M317.11M423.32M337.92M17.66M24.23M-61.92M-42.17M-37.75M-40.12M4.02M-25.86M
Operating Margin %43.67%21.39%2.69%-14.27%-8.99%26.93%-24.11%22.68%33.03%36.87%34.88%12.23%19.85%-515.18%-2849.26%-4701.37%-37851.89%10.59%-290.93%
Operating Income Growth %-728.13%120.51%-92.59%-138.03%236.54%-187.64%-43.87%-25.09%25.27%1812.93%-27.09%139.13%-46.84%-11.7%5.91%-1099.08%115.53%-
EBITDA613M285M60M-141M-65M235M-130M206M333.11M436.32M351.92M18.59M25.16M-61.18M-41.3M-36.87M-38.94M5.09M-24.75M
EBITDA Margin %44.61%23%5.05%-12.9%-7.21%29.71%-20.09%26.24%34.7%38%36.32%12.87%20.61%-509.01%-2790.41%-4591.91%-36731.13%13.42%-278.39%
EBITDA Growth %73.65%375%142.55%-116.92%-127.66%280.77%-163.11%-38.16%-23.65%23.98%1793.47%-26.12%141.12%-48.14%-12%5.3%-865.23%120.56%-
D&A (Non-Cash Add-back)13M20M28M15M16M22M26M28M16M13M14M921K928K742K871K879K1.19M1.07M1.11M
EBIT555M284M55M-114M-62M216M-149M202M295.14M193M136.45M20.84M24.83M-84.42M-42.71M-37.6M-39.47M4.14M-24.8M
Net Interest Income-1M-23M-18M8M-10M-22M-17M2M-14M-42M-51M-4.09M-5.27M-7.55M-3.46M-1.83M107K122K-7.62M
Interest Income16M22M23M43M19M4M7M24M17M7M0681K348K299K120K31K107K122K1.06M
Interest Expense17M45M41M35M29M26M24M22M31M49M51M4.77M5.62M7.85M3.58M1.87M008.68M
Other Income/Expense-62M-26M-18M7M-8M-23M-17M2M-14M-56M-51M-6.23M-4.36M-30.35M-4.12M-1.72M649K122K-7.62M
Pretax Income538M239M14M-149M-89M190M-173M180M265.53M143.91M89.75M14.97M19.87M-92.27M-46.28M-39.47M-39.47M4.14M-33.48M
Pretax Margin %39.16%19.29%1.18%-13.63%-9.88%24.02%-26.74%22.93%27.66%12.53%9.26%10.37%16.28%-767.73%-3127.3%-4915.32%-37239.62%10.91%-376.67%
Income Tax88M29M11M-20M-44M-15M-25M46M2.87M82.98M57.69M956K000-16.25M-399K00
Effective Tax Rate %16.36%12.13%78.57%13.42%49.44%-7.89%14.45%25.56%1.08%57.66%64.29%6.39%0%0%0%41.16%1.01%0%0%
Net Income450M210M2M-129M-44M205M-148M134M262.67M60.92M32.05M14.02M19.87M-92.27M-46.28M56M-38.46M460K-33.48M
Net Margin %32.75%16.95%0.17%-11.8%-4.88%25.92%-22.87%17.07%27.36%5.31%3.31%9.7%16.28%-767.73%-3127.3%6974.22%-36285.85%1.21%-376.67%
Net Income Growth %171.08%10400%101.55%-193.18%-121.46%238.51%-210.45%-48.98%331.14%90.08%128.68%-29.47%121.53%-99.36%-182.65%245.6%-8461.52%101.37%-
Net Income (Continuing)450M210M3M-129M-45M205M-148M134M262.67M60.92M32.05M13.94M19.87M-92.27M-46.28M-23.23M-39.08M4.14M-33.48M
Discontinued Operations0000000000000002.19M000
Minority Interest0000000000000000000
EPS (Diluted)3.691.640.02-0.91-0.371.31-1.080.921.750.410.220.280.32-2.90-2.653.64-2.78-0.21-2.42
EPS Growth %175.38%10833.33%101.65%-145.95%-128.24%221.3%-217.39%-47.43%326.83%86.36%-21.43%-12.5%111.03%-9.43%-172.8%230.94%-1223.81%91.32%-
EPS (Basic)-1.680.02-0.94-0.371.38-1.080.951.810.420.220.290.47-2.90-2.653.64-2.78-0.21-2.42
Diluted Shares Outstanding122M128M133M141.8M139.01M154.23M146.57M151.07M150.23M149.7M148.64M51.16M50.58M31.85M17.44M13.86M13.86M13.86M13.86M
Basic Shares Outstanding118M125M132M137.31M139.01M145.66M146.57M146.05M145.43M144.23M143.97M47.49M42.26M31.82M17.44M13.86M13.86M13.86M13.86M
Dividend Payout Ratio----------215.28%--------

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetAdequate
Cash FlowStable
Top Statement Risk

Volatile quarterly profitability

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Revenue Rebound Lacks Consistent Momentum

According to the supplied quarterly income statements, SUPN revenue rose from $149.8M in 2025Q1 to $356.0M in 2026Q3, yet growth rates have swung between negative and triple-digit percentages, signaling lumpy rather than durable expansion.

The jump to $356.0M in 2026Q3 against a 85.3% year-over-year gain is the single largest data point in the set and may reflect a one-time or lumpy contribution rather than a repeatable run rate. Sequential revenue was flat-to-down across 2026Q1 and 2026Q2, which suggests the top line depends heavily on specific product or licensing events. Investors should monitor whether the 2026Q3 level holds in subsequent quarters before extrapolating growth.

Gross Margins Hold Near Ninety Percent

As reported in the income statement history, SUPN gross margin has stayed between 84.6% and 90.1% across all ten quarters, indicating a high-margin product mix with limited cost-driven variability.

A consistently high gross margin points to a specialty pharmaceutical profile where cost of goods is a small share of revenue. The stability across both growth and contraction periods suggests pricing power has not been materially eroded. The margin level sits well above generic manufacturers but the data alone cannot confirm how much of it is structurally durable versus product-cycle dependent.

Operating Leverage Turns Sharply Volatile

Based on the reported figures, SUPN operating margin swung from 23.2% in 2024Q3 to -31.4% in 2025Q3, showing that fixed operating spend magnifies revenue swings in both directions.

Operating expenses have remained relatively elevated against revenue, so modest top-line shortfalls translate into outsized operating losses. The 2025Q3 and 2026Q2 operating losses coincided with spikes in SG&A relative to revenue, which suggests the cost base was not flexed down with sales. This operating leverage cuts both ways and warrants further investigation into the drivers of those expense peaks.

Net Income Tracks Operating Volatility Closely

According to the supplied EPS figures, SUPN diluted EPS ranged from -$1.01 to $1.12 over ten quarters, and net income moved in step with operating income rather than being buoyed by non-operating items.

Because net income broadly mirrors operating income, the earnings base does not appear to rely heavily on below-the-line gains, which is a constructive quality signal. Stock-based compensation remained in a relatively narrow band for most quarters, though the 2025Q4 SBC figure stands out and warrants checking against the filing. Earnings per share volatility of this magnitude makes trailing valuation ratios unreliable as a guide.

Quarterly Swings Challenge the Recovery Thesis

The strongest challenge to the income statement narrative is that SUPN has posted alternating profitable and loss-making quarters, with two sizable operating losses in the last five periods, which may undermine confidence in sustained profitability.

A bear case would argue that the 2026Q3 profit is an outlier against a pattern of repeated losses, including -$60.2M operating income in 2025Q3 and -$58.0M in 2026Q2. Peer comparisons show SUPN lagging on net margin relative to higher-margin peers such as ACAD and INVA, which suggests the cost structure may be less efficient. Whether the recent profitability proves durable is an open question the reported figures alone cannot resolve.

SUPN — Frequently Asked Questions

Quick answers to the most common questions about buying SUPN stock.

What was Supernus Pharmaceuticals, Inc.'s (SUPN) revenue in 2025?

For fiscal year 2025, Supernus Pharmaceuticals, Inc. (SUPN) reported total revenue of $1.24B. This represents a 13838.6% increase compared to $8.9M in 2008.

Is Supernus Pharmaceuticals, Inc. (SUPN) profitable?

Supernus Pharmaceuticals, Inc. (SUPN) is profitable, generating $210.0M in net income for the fiscal year ending 2025 with a net profit margin of 16.9%.

What is Supernus Pharmaceuticals, Inc.'s operating profit margin?

Supernus Pharmaceuticals, Inc. (SUPN) reported an operating income of $265.0M, resulting in an operating profit margin of 21.4%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Supernus Pharmaceuticals, Inc.'s gross profit and gross margin?

Supernus Pharmaceuticals, Inc. (SUPN) generated $993.0M in gross profit for the year, representing a gross profit margin of 80.1%. This demonstrates the company's core pricing power and production efficiency.